C1S C1S 1 month ago | Other | €0.33 Per Share |
C1S C1S 9 months ago | Other | €0.1 Per Share |
C1S C1S 29 Apr 2024 | Other | €0.4 Per Share |
C1S C1S 12 Sep 2023 | Other | €0.1 Per Share |
C1S C1S 28 Apr 2023 | Other | €0.31 Per Share |
27 Aug 2025 (70 Days) Date | | - Cons. EPS | - EPS |
28 Mar 2025 Date | | - Cons. EPS | - EPS |
26 Mar 2025 Date | | - Cons. EPS | - EPS |
29 Aug 2024 Date | | - Cons. EPS | - EPS |
28 Aug 2024 Date | | - Cons. EPS | - EPS |
C1S C1S 1 month ago | Other | €0.33 Per Share |
C1S C1S 9 months ago | Other | €0.1 Per Share |
C1S C1S 29 Apr 2024 | Other | €0.4 Per Share |
C1S C1S 12 Sep 2023 | Other | €0.1 Per Share |
C1S C1S 28 Apr 2023 | Other | €0.31 Per Share |
27 Aug 2025 (70 Days) Date | | - Cons. EPS | - EPS |
28 Mar 2025 Date | | - Cons. EPS | - EPS |
26 Mar 2025 Date | | - Cons. EPS | - EPS |
29 Aug 2024 Date | | - Cons. EPS | - EPS |
28 Aug 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Zhenjiang Li CEO | XMUN Exchange | KYG2110P1000 ISIN |
CN Country | 3,220 Employees | 30 Apr 2025 Last Dividend | - Last Split | - IPO Date |
China Shineway Pharmaceutical Group Limited operates as an investment holding entity primarily focused on the research, development, manufacturing, and trading of Chinese medicines. Established in 2002 and headquartered in Shijiazhuang, within the People’s Republic of China, it has cemented its presence in both the local Chinese market and Hong Kong. The company’s commitment to enhancing traditional Chinese medicine (TCM) is reflected through its wide range of product offerings and its expansion into various therapeutic domains. As a subsidiary of Forway Investment Limited, China Shineway Pharmaceutical continues to explore innovative solutions within the TCM industry, alongside its engagement in the trading of agricultural products, marking its diversified interests and business model adaptation to the evolving market needs and opportunities.
China Shineway Pharmaceutical has developed a range of soft capsules aimed at treating various health conditions. These capsules are designed to provide patients with an easy-to-consume form of traditional Chinese medicine, focusing on improving user compliance and medication absorption.
As part of its product lineup, the company offers granules, another popular form of traditional Chinese medicine. These granules are tailored for specific health conditions, providing a precise dosage that ensures effectiveness while maintaining the integrity of traditional medicinal practices.
In addition to oral formulations, China Shineway Pharmaceutical produces injections derived from TCM ingredients. These injections target severe or acute conditions, offering a potent and direct therapeutic effect that is critical for certain types of diseases and patients.
The company has also specialized in TCM formula granules, which encompass a variety of therapeutic areas such as respiratory, digestive, cardiovascular, and cerebrovascular diseases, orthopedics, pediatrics, and nervous system disorders. These formula granules are designed for the specific needs of different patient groups, focusing on both curing and preventing diseases with roots in TCM philosophy.
Beyond treating specific ailments, China Shineway Pharmaceutical offers medications aimed at strengthening the body's immune system and overall health. These products are grounded in the preventive aspect of traditional Chinese medicine, emphasizing wellness and the promotion of long-term health.
Expanding its business horizon, the company engages in the trading of agricultural products. This diversification reflects its strategic adaptation to market trends and its endeavor to leverage the extensive network and expertise developed through its core operations in pharmaceuticals.